Redeye is especially encouraged to see that the safety looks good after the nearly year-long study and that the efficacy signals observed in the double-blinded are reinforced. The phase 2 results in hypothalamic obesity (HO) strongly merits further development and that tesomet holds the potential as a potential efficacious treatment in this indication, in our view. To reflect our increased confidence in this program, we raise our Base Case with immediate effect.